Enobosarm is under clinical development by Veru and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Enobosarm’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Enobosarm overview
Enobosarm (Ostarine, GTx-024, MK-2866) is under development for the treatment of preserve muscle mass during weight-loss therapy of older patients with obesity, . It is is a non-steroidal, selective androgen receptor agonist that acts as selective androgen receptor modulator (SARM). It is a new chemical entity and is administered by oral route. It was also under development for the prevention of muscle wasting (cancer cachexia), sarcopenia and stress urinary incontinence (SUI) and duchenne muscular dystrophy androgen receptor-positive triple negative breast cancer, estrogen receptor positive/androgen receptor-positive and HER2 negative breast cancer.
Veru overview
Veru is a biopharmaceutical company that focused on development and commercialization of novel medicines for COVID-19, ARDS-related diseases and novel oncology medicines. It is headquartered in Miami, Florida, the US.
For a complete picture of Enobosarm’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
